Drug Profile

ST 102

Alternative Names: ST-102

Latest Information Update: 28 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SemaThera
Class Eye disorder therapies
Mechanism of Action Semaphorin inhibitors; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Apr 2022 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in Canada (Intravitreous, Injection)
21 Mar 2018 SemaThera signs an option of license agreement with Senju Pharmaceutical to develop and market ST 102 in China and Japan for Diabetic macular oedema
21 Mar 2018 Preclinical trials in Diabetic macular oedema in Canada (Intravitreous)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com